Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: March 26, 2012
Last updated: August 24, 2016
Last verified: August 2016
This two-cohort, open-label, multicenter, phase II study will assess the safety and efficacy of pertuzumab given in combination with Herceptin (trastuzumab) and vinorelbine in first line in patients with metastatic or locally advanced HER2-positive breast cancer. Patients will receive pertuzumab 840 mg and Herceptin 8 mg/kg administered sequentially as separate iv infusions on Days 1 and 2, respectively, of Cycle 1. From Cycle 2 onwards, patients will receive pertuzumab 420 mg and Herceptin 6 mg/kg, administered either sequentially as separate iv infusions on Day 1 and Day 1 or 2, respectively (Cohort 1) or together in one infusion bag on Day 1 (Cohort 2) every 3 weeks. Vinorelbine will be administered at 25 mg/m2 iv on Days 2 and 9 of Cycle 1, and at 30-35 mg/m2 on Days 1 and 8 (or Days 2 and 9) of each following 3-week cycle. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs, or withdrawal of consent or death.

Condition Intervention Phase
Breast Cancer
Drug: pertuzumab
Drug: trastuzumab [Herceptin]
Drug: vinorelbine
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Overall response rates (ORR) assessed by the investigator [ Time Frame: approximately 3.5 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Abnormal laboratory finding [ Time Frame: approximately 3.5 years ] [ Designated as safety issue: No ]
  • Time to response [ Time Frame: approximately 3.5 years ] [ Designated as safety issue: No ]
  • Duration of response [ Time Frame: approximately 3.5 years ] [ Designated as safety issue: No ]
  • Progression-free survival (PFS) [ Time Frame: approximately 3.5 years ] [ Designated as safety issue: No ]
  • Time to progression (TTP) [ Time Frame: approximately 3.5 years ] [ Designated as safety issue: No ]
  • Overall survival (OS) [ Time Frame: approximately 3.5 years ] [ Designated as safety issue: No ]
  • Safety: Incidence of adverse events [ Time Frame: approximately 3.5 years ] [ Designated as safety issue: No ]
  • Cardiac safety: Incidence of congestive heart failure/change in LVEF [ Time Frame: approximately 3.5 years ] [ Designated as safety issue: No ]
  • Quality of life: EQ-5D/FACT-B questionnaires [ Time Frame: approximately 3.5 years ] [ Designated as safety issue: No ]

Enrollment: 214
Study Start Date: April 2012
Study Completion Date: October 2015
Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort 1 Sequential administration Drug: pertuzumab
840 mg iv infusion Day 1 of Cycle 1, followed every 3 weeks by 420 mg iv as separate infusion on Day 1
Drug: trastuzumab [Herceptin]
8 mg/kg iv infusion on Day 2 of Cycle 1, followed every 3 weeks by 6 mg/kg iv as separate infusion on Day 1 or 2
Drug: vinorelbine
25 mg/m2 iv infusion on Days 2 and 9 of Cycle 1, followed by 30-35 mg/m2 on Days 1 and 8 (or Days 2 and 9) of each 3-week cycle
Experimental: Cohort 2 Single infusion admin Drug: pertuzumab
840 mg iv infusion Day 1 of Cycle 1, followed every 3 weeks by 420 mg iv together with trastuzumab in a single infusion bag on Day 1
Drug: trastuzumab [Herceptin]
8 mg/kg iv infusion on Day 2 of Cycle 1, followed every 3 weeks by 6 mg/kg iv together with pertuzumab in a single infusion bag on Day 1
Drug: vinorelbine
25 mg/m2 iv infusion on Days 2 and 9 of Cycle 1, followed by 30-35 mg/m2 on Days 1 and 8 (or Days 2 and 9) of each 3-week cycle


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult patients, >/= 18 years of age
  • Histologically or cytologically confirmed adenocarcinoma of the breast with metastatic or locally advanced disease not amenable to curative resection
  • HER2-positive as assessed by local laboratory on primary or metastatic tumor
  • At least one measurable lesion and/or non-measurable disease evaluable according to RECIST version 1.1 criteria
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Left ventricular ejection fraction (LVEF) of at least 55%
  • Life expectancy of at least 12 weeks

Exclusion Criteria:

  • Previous systemic non-hormonal anticancer therapy in the metastatic or locally advanced setting
  • Previous approved or investigative anti-HER2 agents in any breast cancer treatment setting, except trastuzumab and/or lapatinib in the adjuvant or neoadjuvant setting
  • Disease progression while receiving trastuzumab and/or lapatinib in the adjuvant or neoadjuvant setting
  • Disease-free interval from completion of adjuvant or neoadjuvant systemic non-hormonal treatment to recurrent disease of less than 6 months
  • History of persistent Grade 2 or higher (NCI-CTC Version 4.0) hematological toxicity resulting from previous adjuvant or neoadjuvant therapy
  • Radiographic evidence of central nervous system (CNS) metastases
  • Current peripheral neuropathy of Grade 3 or greater
  • History of other malignancy within the last 5 years, except for carcinoma in situ of the cervix or basal cell carcinoma
  • Serious uncontrolled concomitant disease that would contraindicate the use of any of the investigational drugs used in this study or would put the patients at high risk for treatment -related complications
  • Inadequate hematologic, liver or renal function
  • Uncontrolled hypertension or clinically significant cardiovascular disease
  • Hepatitis B, hepatitis C or HIV infection
  • Current chronic daily treatment with corticosteroids (>/= 10 mg/day methylprednisolone or equivalent), excluding inhaled steroids
  • Radiographic evidence of central nervous system (CNS) metastases that are not well controlled with continuous corticosteriod therapy.
  • History of other malignancy within the last 5 years, except for carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage 1 uterine cancer, or cancers with a similar curative outcome as those mentioned above
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01565083

  Hide Study Locations
United States, Arizona
Tucson, Arizona, United States, 85724
United States, California
Stanford, California, United States, 94305-5151
United States, Colorado
Denver, Colorado, United States, 80220
United States, Florida
Hollywood, Florida, United States, 33021
Miami, Florida, United States, 33136
Plantation, Florida, United States, 33324
United States, Georgia
Marietta, Georgia, United States, 30060
United States, Massachusetts
Boston, Massachusetts, United States, 02215
United States, New Jersey
Morristown, New Jersey, United States, 07960
United States, North Carolina
Durham, North Carolina, United States, 27710
United States, Ohio
Columbus, Ohio, United States, 43210
United States, Texas
Houston, Texas, United States, 77090
San Antonio, Texas, United States, 78229
United States, Utah
Ogden, Utah, United States, 84403
United States, Virginia
Fredericksburg, Virginia, United States, 22408
United States, Washington
Seattle, Washington, United States, 98101
Seattle, Washington, United States, 98195
Rio de Janeiro, RJ, Brazil, 20560-120
Barretos, SP, Brazil, 14784-400
Sao Paulo, SP, Brazil, 01308-050
Sao Paulo, SP, Brazil, 01317-000
Sao Paulo, SP, Brazil, 04039-901
Herlev, Denmark, 2730
Herning, Denmark, 7400
København Ø, Denmark, 2100
Odense, Denmark, 5000
Avignon, France, 84082
Bobigny, France, 93009
Caen, France, 14076
La Tronche, France, 38700
Mont-de-marsan, France, 40024
Paris, France, 75651
Paris, France, 75908
Perigueux, France, 24000
Pierre Benite, France, 69495
Plerin, France, 22190
Rouen, France, 76038
Strasbourg, France, 67065
Tours, France, 37044
Villejuif, France, 94805
Dortmund, Germany, 44263
Dresden, Germany, 01307
Frankfurt am Main, Germany, 60389
Freiburg, Germany, 79110
Georgsmarienhütte, Germany, 49124
Goslar, Germany, 38642
Gütersloh, Germany, 33332
Hamburg, Germany, 20357
Heidelberg, Germany, 69115
Kaiserslautern, Germany, 67655
Kassel, Germany, 34119
Köln, Germany, 50677
Lebach, Germany, 66822
Leer, Germany, 26789
Moers, Germany, 47441
München, Germany, 80335
München, Germany, 80639
Neumarkt, Germany, 92318
Ravensburg, Germany, 88212
Wuerselen, Germany, 52146
Bologna, Emilia-Romagna, Italy, 40138
Aviano, Friuli-Venezia Giulia, Italy, 33081
Roma, Lazio, Italy, 00189
Genova, Liguria, Italy, 16132
Cremona, Lombardia, Italy, 26100
Monza, Lombardia, Italy, 20900
Lido Di Camaiore, Toscana, Italy, 55043
Pisa, Toscana, Italy, 56100
Terni, Umbria, Italy, 05100
Negrar, Veneto, Italy, 37024
Oviedo, Asturias, Spain, 33006
Terrassa, Barcelona, Spain, 08227
Santander, Cantabria, Spain, 39008
Barbastro, Huesca, Spain, 22300
Palma de Mallorca, Islas Baleares, Spain, 07198
La Laguna, Tenerife, Spain, 38320
Badajoz, Spain, 06080
Madrid, Spain, 28223
Malaga, Spain, 29010
Valencia, Spain, 46014
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche Identifier: NCT01565083     History of Changes
Other Study ID Numbers: MO27782  2011-003308-18 
Study First Received: March 26, 2012
Last Updated: August 24, 2016
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on October 21, 2016